Neurofibromatosis Type 1 and tumorigenesis: Molecular mechanisms and therapeutic implications

Neurosurgical Focus

Volumn 28, Issue 1, 2010, Pages

  Gottfried, Oren N ^a   Viskochil, David H ^a   Couldwell, William T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Loss of heterozygosity; Malignant peripheral nerve sheath tumor; Neurofibroma; Optic nerve glioma; Plexiform neurofibroma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; SIGNAL PEPTIDE;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; DISEASE MODEL; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MOUSE; MUTATION; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENES, NEUROFIBROMATOSIS 1; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, GENETIC; MUTATION; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OPTIC NERVE GLIOMA; PROTEIN-SERINE-THREONINE KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 76549123056     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2009.11.FOCUS09221     Document Type: Review

References (114)

1. Ahmadian MR, Wiesmüller L, Lautwein A, Bischoff FR, Wittinghofer A: Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. J Biol Chem 271:16409-16415, 1996
2. Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 9:535-539, 2009
3. Appenzeller O, Kornfeld M, Atkinson R, Snyder RD: Neurofibromatosis xenografts. Contribution to pathogenesis. J Neurol Sci 74:69-77, 1986
4. Ars E, Serra E, García J, Kruyer H, Gaona A, Lázaro C, et al: Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet 9:237-247, 2000
5. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, et al: Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63:8573-8577, 2003
6. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, et al: The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63:851-859, 1990
7. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715, 1992
8. Bernards A: Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta 1242:43-59, 1995
9. Bernards A, Haase VH, Murthy AE, Menon A, Hannigan GE, Gusella JF: Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and absence of expression in a neuroblastoma line. DNA Cell Biol 11:727-734, 1992
10. Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, et al: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer [epub ahead of print], 2009
11. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, et al: Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81:833-844, 2001
12. Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, et al: Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 29:3964-3974, 2009
13. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148, 1996
14. Bollag G, McCormick F: Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 351: 576-579, 1991
15. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, et al: Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029, 1994
16. Brems H, Beert E, de Ravel T, Legius E: Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508-515, 2009
17. Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG: Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 347:291-294, 1990
18. Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and Its Coverings, ed 4. New York: Churchill Livingstone, 2002
19. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201, 1990
20. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al: Mouse models of tumor development in neurofibromatosis type 1. Science 286:2172-2176, 1999
21. Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334, 1998
22. Coussens LM, Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002
23. Coussens LM, Werb Z: Inflammatory cells and cancer: think different! J Exp Med 193:F23-F26, 2001
24. Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N: The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 8:415-428, 1992
25. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, et al: Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273, 1992
26. Denayer E, de Ravel T, Legius E: Clinical and molecular aspects of RAS related disorders. J Med Genet 45:695-703, 2008
27. Downward J: Ras signalling and apoptosis. Curr Opin Genet Dev 8:49-54, 1998
28. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92:7686-7689, 1995
29. Dunn NR, Winnier GE, Hargett LK, Schrick JJ, Fogo AB, Hogan BL: Haploinsufficient phenotypes in Bmp4 heterozygous null mice and modification by mutations in Gli3 and Alx4. Dev Biol 188:235-247, 1997
30. Ehninger D, de Vries PJ, Silva AJ: From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res 53:838-851, 2009
31. Eisenbarth I, Beyer K, Krone W, Assum G: Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet 66:393-401, 2000
32. Elyakim S, Lerer I, Zlotogora J, Sagi M, Gelman-Kohan Z, Merin S, et al: Neurofibromatosis type I (NFI) in Israeli families: linkage analysis as a diagnostic tool. Am J Med Genet 53:325-334, 1994
33. Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kücükceylan N, et al: Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet 66:790-818, 2000
34. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632, 1998
35. Friedman JM: Clinical genetics, in Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (eds): Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, ed 3. Baltimore: Johns Hopkins University Press, 1999, pp 110-118
36. Gavrilovic J, Brennan A, Mirsky R, Jessen KR: Fibroblast growth factors and insulin growth factors combine to promote survival of rat Schwann cell precursors without induction of DNA synthesis. Eur J Neurosci 7:77-85, 1995
37. Glover TW, Stein CK, Legius E, Andersen LB, Brereton A, Johnson S: Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 3:62-70, 1991
38. Gottfried ON, Viskochil DH, Fults DW, Couldwell WT: Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications. Neurosurgery 58:1-16, 2006
39. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, et al: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12:507-513, 1996
40. Gutmann DH, Geist RT, Wright DE, Snider WD: Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ 6:315-323, 1995
41. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
42. Hegedus B, Banerjee D, Yeh TH, Rothermich S, Perry A, Rubin JB, et al: Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 68:1520-1528, 2008
43. Hesselager G, Holland EC: Using mice to decipher the molecular genetics of brain tumors. Neurosurgery 53:685-695, 2003
44. Huang J, Wu S, Wu CL, Manning BD: Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 69:6107-6114, 2009
45. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, et al: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191:181-188, 2000
46. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA: Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353-361, 1994
47. Jadayel D, Fain P, Upadhyaya M, Ponder MA, Huson SM, Carey J, et al: Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature 343:558-559, 1990
48. Jessen KR, Mirsky R: Origin and early development of Schwann cells. Microsc Res Tech 41:393-402, 1998
49. Jhanwar SC, Chen Q, Li FP, Brennan MF, Woodruff JM: Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet 78:138-144, 1994
50. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, et al: TORC1 is essential for NF1-associated malignancies. Curr Biol 18:56-62, 2008
51. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102:8573-8578, 2005
52. John AM, Ruggieri M, Ferner R, Upadhyaya M: A search for evidence of somatic mutations in the NF1 gene. J Med Genet 37:44-49, 2000
53. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, et al: The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 13:129-140, 2008
54. Katz D, Lazar A, Lev D: Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med 11:e30, 2009
55. Kim HA, Rosenbaum T, Marchionni MA, Ratner N, DeClue JE: Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11:325-335, 1995
56. Kioussi C, Gruss P: Making of a Schwann. Trends Genet 12:84-86, 1996
57. Kluwe L, Friedrich R, Mautner VF: Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 24: 283-285, 1999
58. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M: Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis. Cancer Genet Cytogenet 136:113-120, 2002
59. Korf BR: Neurofibromas and malignant tumors of the peripheral nerve sheath, in Friedman JM, Gutmann DH, MacCollin M (eds): Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, ed 3. Baltimore: Johns Hopkins University Press, 1999, pp 142-161
60. Lakkis MM, Epstein JA: Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359-4367, 1998
61. Le LQ, Shipman T, Burns DK, Parada LF: Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 4:453-463, 2009
62. Lee JK, Sobel RA, Chiocca EA, Kim TS, Martuza RL: Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol 14:101-112, 1992
63. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, et al: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10:250-255, 1994
64. Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, et al: Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 137:908-913, 2001
65. Liapis H, Marley EF, Lin Y, Dehner LP: p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr Dev Pathol 2:377-384, 1999
66. Luria D, Avigad S, Cohen IJ, Stark B, Weitz R, Zaizov R: p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type 1. Cancer 80:2013-2018, 1997
67. Marchuk DA, Tavakkol R, Wallace MR, Brownstein BH, Taillon-Miller P, Fong CT, et al: A yeast artificial chromosome contig encompassing the type 1 neurofibromatosis gene. Genomics 13:672-680, 1992
68. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843-849, 1990
69. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A: The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20:97-105, 2001
70. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, et al: Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16:44-54, 2009
71. McLaughlin ME, Jacks T: Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. Cancer Cell 1:408-410, 2002
72. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, et al: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neu ro fibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 87:5435-5439, 1990
73. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al: Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541-555, 2000
74. Mi R, Ma J, Zhang D, Li L, Zhang H: Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J Genet Genomics 36:355-361, 2009
75. Mozaffari M, Hoogeveen-Westerveld M, Kwiatkowski D, Sampson J, Ekong R, Povey S, et al: Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Med Genet 10:88, 2009
76. Muir D: Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin Exp Metastasis 13:303-314, 1995
77. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR: Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 158:501-513, 2001
78. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989
79. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
80. Peltonen J, Jaakkola S, Lebwohl M, Renvall S, Risteli L, Virtanen I, et al: Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. Lab Invest 59:760-771, 1988
81. Pineda A: Electron microscopy of the lemmocyte in peripheral nerve tumors (neurolemmomas). J Neurosurg 25:35-44, 1966
82. Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, et al: Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 28: 425-431, 2000
83. Ratner N, Lieberman MA, Riccardi VM, Hong DM: Mitogen accumulation in von Recklinghausen neurofibromatosis. Ann Neurol 27:298-303, 1990
84. Rodenhiser DI, Andrews JD, Mancini DN, Jung JH, Singh SM: Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumour-suppressor gene. Mutat Res 373:185-195, 1997
85. Sanguinetti C, Greco F, de Palma L, Specchia N, Toesca A, Nori S: The ultrastructure of schwannoma and neurofibroma of the peripheral nerves. Ital J Orthop Traumatol 17:237-246, 1991
86. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, Viskochil D: Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 14:110-112, 1996
87. Serra E, Ars E, Ravella A, Sánchez A, Puig S, Rosenbaum T, et al: Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 108:416-429, 2001
88. Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, et al: Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 9:3055-3064, 2000
89. Sheela S, Riccardi VM, Ratner N: Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol 111:645-653, 1990
90. Stefansson K, Wollmann R, Jerkovic M: S-100 protein in softtissue tumors derived from Schwann cells and melanocytes. Am J Pathol 106:261-268, 1982
91. Sternberg PW, Alberola-Ila J: Conspiracy theory: RAS and RAF do not act alone. Cell 95:447-450, 1998
92. Tidyman WE, Rauen KA: The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230-236, 2009
93. Trahey M, McCormick F: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545, 1987
94. Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF: Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet 46:81-85, 2009
95. Upadhyaya M, Han S, Consoli C, Majounie E, Horan M, Thomas NS, et al: Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 23:134-146, 2004
96. Upadhyaya M, Maynard J, Osborn M, Huson SM, Ponder M, Ponder BA, et al: Characterisation of germline mutations in the neurofibromatosis type 1 (NF1) gene. J Med Genet 32:706-710, 1995
97. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, et al: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192, 1990
98. Viskochil DH: The structure and function of the NF1 gene: molecular pathophysiology, in Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (eds): Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, ed 3. Baltimore: Johns Hopkins University Press, 1999, pp 119-141
99. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248, 1994
100. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF: Mouse tumor model for neurofibromatosis type 1. Science 286:2176-2179, 1999
101. von Deimling A, Foster R, Krone W: Familial tumour syndromes involving the nervous system, in Kleihues P, Cavenee WK (eds): Pathology and Genetics: Tumours of the Nervous System. Lyon: IARC Press, 2000, pp 216-218
102. Waggener JD: Ultrastructure of benign peripheral nerve sheath tumors. Cancer 19:699-709, 1966
103. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186, 1990
104. Weiss B, Bollag G, Shannon K: Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14-22, 1999
105. Woodruff JM: Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am J Med Genet 89:23-30, 1999
106. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, et al: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63:835-841, 1990
107. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al: The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608, 1990
108. Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V: Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res 55:3569-3575, 1995
109. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, et al: Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/-mast cells. J Clin Invest 112:1851-1861, 2003
110. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, et al: Nf1-dependent tumors require a microenvironment containing Nf1+/-and c-kit-dependent bone marrow. Cell 135:437-448, 2008
111. Yao R, Cooper GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006, 1995
112. Yeh TH, Lee Y, Gianino SM, Gutmann DH: Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 57:1239-1249, 2009
113. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, et al: Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 13:117-128, 2008
114. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-922, 2002